Syros Pharmaceuticals (SYRS) - Rasio rega marang prakiraan pendapatan
Syros Pharmaceuticals (SYRS) is developing advanced gene expression modulation methods to combat hematologic malignancies, mitigating risks through research diversification. The GURU.Markets platform reports the firm's forward P/S, where the 8.20 mark characterizes this parameter. Despite fierce competition with pharma behemoths, Syros Pharmaceuticals is actively expanding its drug portfolio, planning the launch of a therapy for acute myeloid leukemia by 2026.
SYRS (Syros Pharmaceuticals, Inc): rincian analitis lan laporan miturut indikator
- rega pasar lan target rega analis:
- indikator kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Syros Pharmaceuticals|SYRS - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Syros Pharmaceuticals|SYRS - Gunggung utang perusahaan|Utang marang nilai buku Syros Pharmaceuticals, Inc|SYRS - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Syros Pharmaceuticals|Rasio cepet syros.com
- rincian asil keuangan lan kelipatan valuasi:
SYRS - Penghasilan resik|Proyeksi bathi mangsa ngarep Syros Pharmaceuticals|SYRS - Pangali P/E|Rega marang bathi mangsa ngarep Syros|SYRS - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Syros Pharmaceuticals, Inc|SYRS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Syros Pharmaceuticals|SYRS - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan syros.com|SYRS - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Syros Pharmaceuticals
- data total pendapatan lan volume dodolan:
Analisis fundamental perusahaan:Syros Pharmaceuticals, Inc. (SYRS)
High binary risks for Syros Pharmaceuticals (SYRS) due to its dependence on a single leukemia drug make the valuation critically dependent on future cash flows. By analyzing the projected market cap-to-revenue ratio, an investor compares the current market price of the business with expected sales volume, allowing for a mathematical assessment of whether the asset is overvalued or undervalued and determining capital resilience during periods of volatility.
Perusahaan pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rega forward marang dodolan QGEN|IONS - Rasio rega marang prakiraan pendapatan|Repligen Inc. (RGEN) - Multiplikator forward rega marang pendapatan|RNA: Multiplikator Forward P/S|crisprtx.com (CRSP) - Multiplikator Forward P/S|WGS (GeneDx) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Ultragenyx Pharmaceutical Inc. (RARE)|Multiplikator Forward P/S BEAM|SRPT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Twist Bioscience - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S 10xgenomics.com TXG|NTLA: Multiplikator forward rega marang pendapatan|Stoke Therapeutics Inc - Rasio rega marang pendapatan sing dikarepake|BLFS: Multiplikator Forward P/S|WVE - Rasio kapitalisasi marang dodolan sing dikarepake|MAZE (Maze Therapeutics Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan sionnatx.com (SION)|Multiplikator Forward P/S PRME|Multiplikator Forward P/S Taysha Gene Therapies Inc (TSHA)|Rasio rega marang prakiraan pendapatan uniQure Corp QURE|MeiraGTx Corp - Rasio rega marang prakiraan pendapatan|RGNX - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake solidbio.com SLDB|Ocugen (OCGN) - Rasio rega marang prakiraan pendapatan|PACB - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan BNTC|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Design Corp DSGN|Rasio rega marang prakiraan pendapatan Rocket Pharmaceuticals (RCKT)|FDMT (4dmoleculartherapeutics.com) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|Rasio kapitalisasi marang dodolan sing dikarepake Korro Bio Inc. (KRRO)|Editas - Multiplikator Forward P/S|SLN (Silence Therapeutics Corp) - Kapitalisasi marang prakiraan pendapatan|proqr.com (PRQR) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan CDXS|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Multiplikator Forward P/S Nautilus Biotechnology Inc|Rasio rega marang prakiraan pendapatan Metagenomi, Inc (MGX)|Rasio kapitalisasi marang dodolan sing dikarepake Precision BioSciences Inc.|Generation Bio - Multiplikator forward rega marang pendapatan|boundlessbio.com (BOLD) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|XCUR - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan IMNN (Imunon, Inc.)|phiopharma.com (PHIO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Mustang Bio (MBIO)|Rasio rega marang prakiraan pendapatan TransCode Therapeutics Inc.|Bionano (BNGO) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan APDN (Applied DNA Sciences, Inc.)|BLUE (bluebird bio Inc.) - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan ImmunoPrecise Antibodies Ltd. IPA|OMGA (Omega Therapeutics Corp) - Rega mangsa ngarep marang pendapatan|Singular Genomics Systems - Multiplikator Forward P/S|Rega forward marang dodolan RGLS (regulusrx.com)|TBIO: Multiplikator Forward P/S|TRACON Pharmaceuticals Inc. (TCON) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Unity Bio
